Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an Executive Director, Healthcare Law and Market Access reporting to the Vice President, Healthcare Law to join our RevMed team. The Executive Director, Healthcare Law and Market Access will serve as the zoldonrasib Legal brand lead and provide strategic legal guidance related to the company’s planned zoldonrasib commercialization activities, patient access programs, distribution and licensing, and regulatory submissions. In addition, the position will serve as the senior enterprise legal leader responsible for shaping and advancing Revolution Medicines’ U.S. Market Access legal strategy in support of commercialization, patient access, pricing, reimbursement, and corporate growth objectives. At a tactical level, the position will be responsible for managing all aspects of Market Access contracting through product distribution channels, including distributors, specialty distributors, specialty pharmacies, 3rd party logistics providers and payers, and government pricing and reimbursement.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive
Education Level
Ph.D. or professional degree